Crispr/cas-related methods and compositions for knocking out c5
US-2024415980-A1 · Dec 19, 2024 · US
Method for delivering alpha-melanocyte stimulating hormone mimetibody composition comprising propylene glycol for intranasal administration to the central nervous system
US9732147B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9732147-B2 |
| Application number | US-201414495291-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 24, 2014 |
| Priority date | Feb 23, 2005 |
| Publication date | Aug 15, 2017 |
| Grant date | Aug 15, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Pharmaceutical compositions and methods for delivering a polypeptide to the central nervous system of a mammal via intranasal administration are provided. The polypeptide can be a catalytically active protein or an antibody, antibody fragment or antibody fragment fusion protein. The polypeptides are formulated with one or more specific agents.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of delivering a polypeptide to the brain of a human across nasal epithelium along olfactory and trigeminal nerve pathways, comprising: a) providing a pharmaceutical composition comprising i) a polypeptide that binds to a melanocortin 4 receptor and comprises an antibody Fc or a mimetibody comprising an antibody Fc fragment and is soluble in the pharmaceutical composition: and ii) from 10 ml to 20 ml of propylene glycol per 100 ml of the pharmaceutical composition; and b) administering the pharmaceutical composition to the nasal cavity of the animal, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1, 2 or 3.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Drugs for disorders of the cardiovascular system · CPC title
for hyperglycaemia, e.g. antidiabetics · CPC title
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9732147B2 cover?
- Pharmaceutical compositions and methods for delivering a polypeptide to the central nervous system of a mammal via intranasal administration are provided. The polypeptide can be a catalytically active protein or an antibody, antibody fragment or antibody fragment fusion protein. The polypeptides are formulated with one or more specific agents.
- Who is the assignee on this patent?
- Janssen Biotech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/18. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).